0.7  -0.02 (-2.78%)		04-10 16:00
Open: 0.705 High: 0.7369 Volume: 425,190		Pre. Close: 0.72 Low: 0.69 Market Cap: 5(M)

Short term
Mid term
Targets	6-month :	0.87	1-year :	1.02
Resists	First :	0.75	Second :	0.87
Pivot price	0.75
Supports	First :	0.53	Second :	0.44
MAs	MA(5) :	0.75	MA(20) :	0.77
	MA(100) :	0.88	MA(250) :	0.86
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	60	D(3) :	66.4
RSI	RSI(14): 37
52-week	High :	3.78	Low :	0.28

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ KTTA ] has closed above bottom band by 0.4%. Bollinger Bands are 67.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 24 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	0.74 - 0.74	0.74 - 0.75
Low:	0.68 - 0.69	0.69 - 0.69
Close:	0.69 - 0.7	0.7 - 0.71

Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. The company was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Fri, 10 Apr 2026
Pasithea Therapeutics Corp. (KTTA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Wed, 08 Apr 2026
Opaleye/James Silverman hold 2.49M shares of Pasithea (KTTA) in Schedule 13G - Stock Titan

Wed, 01 Apr 2026
Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 Associated Plexiform Neurofibromas Causing Significant Morbidity - Investing News Network

Wed, 25 Mar 2026
Positive Signs As Multiple Insiders Buy Pasithea Therapeutics Stock - simplywall.st

Tue, 17 Feb 2026
NF1-PN drug developer Pasithea to present at Oppenheimer event - Stock Titan

Tue, 13 Jan 2026
Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines - Investing News Network

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	23 (M)
Shares Float	5 (M)
Held by Insiders	1.6 (%)
Held by Institutions	64.7 (%)
Shares Short	194 (K)
Shares Short P.Month	183 (K)

EPS	-4.43
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	1.63
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-53.8 %
Return on Equity (ttm)	-90 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-0.58
Qtrly Earnings Growth	0 %
Operating Cash Flow	-12 (M)
Levered Free Cash Flow	-8 (M)

PE Ratio	-0.16
PEG Ratio	0
Price to Book value	0.42
Price to Sales	0
Price to Cash Flow	-1.32

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.